| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-81071-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-26688-50ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-26470-50ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-26686-50ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-26634-50ul | |||
![Flow Cytometry: CCR8 Antibody (2C10) [NBP3-26688] - Untransfected CHO-K1 cells (green line) and transfected Human CCR8 CHO-K1 stable cells (red line) were stained with anti-CCR8 antibody (2ug/1*10^6 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.](http://images.novusbio.com/fullsize/nbp3-26688_human-ccr8-mab-2c10-282202414183623.jpg "Flow Cytometry: CCR8 Antibody (2C10) [NBP3-26688] - Untransfected CHO-K1 cells (green line) and transfected Human CCR8 CHO-K1 stable cells (red line) were stained with anti-CCR8 antibody (2ug/1*10^6 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.")
![ELISA: Complement Component C5aR1 Antibody (3A7) [NBP3-26470] - The Binding Activity of Human Complement Component C5aR1 with Complement Component C5aR1 Antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized Human Complement Component C5aR1 at 10 ug/mL can bind Complement Component C5aR1 Antibody, the EC50 is 1.239-3.760 ng/mL.](http://images.novusbio.com/fullsize/nbp3-26470_human-complement-component-c5ar1-mab-3a7-262202412272333.jpg "ELISA: Complement Component C5aR1 Antibody (3A7) [NBP3-26470] - The Binding Activity of Human Complement Component C5aR1 with Complement Component C5aR1 Antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized Human Complement Component C5aR1 at 10 ug/mL can bind Complement Component C5aR1 Antibody, the EC50 is 1.239-3.760 ng/mL.")
![Flow Cytometry: CCR8 Antibody (2C6) [NBP3-26686] - Untransfected HEK293T cells (green line) and transfected Human CCR8 HEK293T stable cells (red line) were stained with anti-CCR8 antibody (2ug/1*10^6 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.](http://images.novusbio.com/fullsize/nbp3-26686_human-ccr8-mab-2c6-28220241431276.jpg "Flow Cytometry: CCR8 Antibody (2C6) [NBP3-26686] - Untransfected HEK293T cells (green line) and transfected Human CCR8 HEK293T stable cells (red line) were stained with anti-CCR8 antibody (2ug/1*10^6 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.")
![Flow Cytometry: DARC Antibody (18B11) [NBP3-26634] - Overlay Peak curve showing 293 cells stained with DARC Antibody (18B11) (red line) at 1:50. The cells were fixed in 4% formaldehyde and permeated by 0.2% Triton X-100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10^6 cells) for 45min at 4C. The secondary antibody used was FITC-conjugated Goat Anti-rabbit IgG (H+L) at 1:200 dilution for 35min at 4C. Control antibody (green line) was rabbit IgG (1ug/1*10^6 cells) used under the same conditions. Acquisition of >10,000 events was performed.](http://images.novusbio.com/fullsize/nbp3-26634_rabbit-darc-mab-18b11-282202414183683.jpg "Flow Cytometry: DARC Antibody (18B11) [NBP3-26634] - Overlay Peak curve showing 293 cells stained with DARC Antibody (18B11) (red line) at 1:50. The cells were fixed in 4% formaldehyde and permeated by 0.2% Triton X-100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10^6 cells) for 45min at 4C. The secondary antibody used was FITC-conjugated Goat Anti-rabbit IgG (H+L) at 1:200 dilution for 35min at 4C. Control antibody (green line) was rabbit IgG (1ug/1*10^6 cells) used under the same conditions. Acquisition of >10,000 events was performed.")